Navigation Links
Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
Date:3/12/2009

high dose. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound. This insertion is very similar to an intravitreal injection, a procedure commonly employed by retinal specialists.

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India, with a combined total enrollment of 956 patients.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, which Alimera is studying as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera has exercised its option to acquire a license with respect to one of these classes of NADPH oxidase inhibitors.


'/>"/>
SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
2. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
3. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
4. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
8. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
9. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
10. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
11. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... cancers and women,s health, has appointed Holly B. ... Markets. Ms. Bauzon has a proven track ... coverage for laboratory services companies. She has more than ... Inc., where she held the position of Director, Lab ...
(Date:8/21/2014)... - Eisai Limited is pleased to support the Canadian Epilepsy ... available in Canada . The comic book, ... children and their parents about epilepsy, the most common neurological ... 300,000 Canadians. Eisai is guided by a corporate philosophy known ... patient is central – there was a need within the ...
(Date:8/21/2014)... MISSION, Kan. , Aug. 21, 2014 /PRNewswire-iReach/ ... Information Trust Alliance (HITRUST) under its Common Security ... ScriptPro,s Enterprise Security and Privacy Manager, "We appreciate ... the level of commitment that this certification signifies. ... compliant." ABOUT THE CSF CERTIFICATION PROCESS: ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2ScriptPro Achieves HITRUST Certification 2
... REDWOOD CITY, Calif., Oct. 19 Ingenuity® Systems, ... science researchers, and TransMed Systems, a translational medicine ... between IPA® software and XB Bio-Integration Suite (XB-BIS). ... data that is managed and statistically analyzed by ...
... Results From the Intermezzo® Highway Driving Study -- POINT RICHMOND, Calif., Oct. 19 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // ...
Cached Medicine Technology:Ingenuity Systems and TransMed Systems Integrate Software to Support Personalized Medicine Research 2Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 2Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 3Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 4Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 5Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 6Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 7Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 8Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 9Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 10Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 11Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 12Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 13Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study 14
(Date:8/21/2014)... (PRWEB) August 22, 2014 Recently, iFitDress.com, a ... gowns, has updated its website with a new range of ... the company’s marketing specialist has announced that all these fashionable ... off. , The marketing specialist says, “We are very ... the moment, we are providing a wide variety of fashionable ...
(Date:8/21/2014)... 22, 2014 DoudouneCanadienneGoosePasCher.fr, one of the ... has recently unveiled its new selection of Trillium Parkas ... announced that all these fashionable and comfortable items are ... special offer will last until September 01. , ... the new Canada Goose Trillium Parkas for ...
(Date:8/21/2014)... 2014 Top10BestSEOHosting.com has recently compared ... iPage ( http://www.top10bestseohosting.com/go/iPage/ ) is one of the ... , The manager of Top10BestSEOHosting.com states, “It is ... Actually, these companies have outperformed their competitors on ... People can get the best web hosting at ...
(Date:8/21/2014)... 21, 2014 Today, Zane Benefits, the ... the premium tax credits in 2015. , According to ... part of the Affordable Care Act (ACA), premium tax ... individual health insurance through the Health Insurance Marketplaces. , ... and the amount of the tax credits, updated for ...
(Date:8/21/2014)... Corona, NY (PRWEB) August 21, 2014 ... new trend among their patients. Alternative medicine is ... to due to millenials. According to The Fiscal ... alternative medical treatments over conventional medicine. , The ... discussing how many millenials are embracing alternative medicine. ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Cheap Plus Size Evening Dresses for 2014 Now Available 2Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:iPage Reviews Unveiled Online At Top10BestSEOHosting.com 2Health News:Van Uden Center Sees Growth in Alternative Medicine 2
... active antiretroviral treatment (HAART) needs to be careful// ... Belgium. ,Highly active antiretroviral treatment can dramatically ... expectancy. This is especially helpful for patients with ... to have a full commitment to the antiviral ...
... neck cancer who are undergoing radiation// therapy can now ... ,Oropharyngeal candidiasis is a fungal infection in the ... also called thrush. The symptoms of the disease are ... when removed leaves a bleeding surface. This is a ...
... often had complained of a sudden increase in weight, especially ... this sudden influx of weight often results in obesity that ... rise in type 2 diabetes cases, cardiovascular diseases and other ... may be due to a drop in the estrogen levels ...
... had affected a total of 423 cases in Angola,// which ... the form of a vaccine. ,A virus causes Marburg ... Ebola hemorrhagic fever. The disease is a rare condition but ... symptoms begin with severe headaches and feeling of severe unwell. ...
... intake of vitamin B may be at less risk from ... of alcohol along with vitamin B may have even reduced ... happens when there is growth of abnormal or malignant cells ... was done by Swedish and American researchers, said that inadequate ...
... an injury to the knee. This may lead to inflammations ... identified a way to find out how much loss of ... in order to find out whether the injury may be ... considered to be a risk factor for arthritis, it was ...
Cached Medicine News:
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
Attain LV Leads. Navigate minimally angled veins with little to moderate tortuosity....
Medicine Products: